Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 49.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 102,595 shares of the company's stock after purchasing an additional 33,897 shares during the quarter. Intech Investment Management LLC owned approximately 0.10% of Neurocrine Biosciences worth $11,821,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC bought a new stake in shares of Neurocrine Biosciences during the second quarter worth $28,000. Innealta Capital LLC acquired a new position in shares of Neurocrine Biosciences during the second quarter worth about $30,000. New Covenant Trust Company N.A. acquired a new position in Neurocrine Biosciences during the first quarter valued at approximately $32,000. EdgeRock Capital LLC acquired a new position in Neurocrine Biosciences during the second quarter valued at approximately $35,000. Finally, Blue Trust Inc. raised its stake in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company's stock valued at $40,000 after buying an additional 220 shares during the period. Institutional investors and hedge funds own 92.59% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Monday, September 16th. HC Wainwright reissued a "buy" rating and set a $190.00 price target on shares of Neurocrine Biosciences in a report on Friday, November 1st. Citigroup boosted their price target on Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a "neutral" rating in a report on Friday, August 2nd. BMO Capital Markets reduced their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating on the stock in a research report on Thursday, October 17th. Finally, Needham & Company LLC restated a "hold" rating on shares of Neurocrine Biosciences in a research report on Monday, November 11th. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $163.91.

Neurocrine Biosciences Stock Performance

NBIX traded up $0.65 during trading on Friday, hitting $125.65. The stock had a trading volume of 1,206,275 shares, compared to its average volume of 874,442. The company has a market capitalization of $12.72 billion, a PE ratio of 33.51 and a beta of 0.35. Neurocrine Biosciences, Inc. has a twelve month low of $110.52 and a twelve month high of $157.98. The stock has a 50 day simple moving average of $118.55 and a two-hundred day simple moving average of $132.13.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.